MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx has raised $125.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2026.
MeiraGTx's investors include Sanofi, Perceptive Advisors, AlbionVC, ATW Partners, UCL Technology Fund.
MeiraGTx is headquartered in New York, United States.
MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MeiraGTx — Funding & Investors." VCBacked, July 7, 2026, https://www.vcbacked.co/company/meiragtx-new-york-2. Accessed October 21, 2026.
VCBacked. (2026). MeiraGTx — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/meiragtx-new-york-2
{{cite web |title=MeiraGTx — Funding & Investors |url=https://www.vcbacked.co/company/meiragtx-new-york-2 |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated